CoChat

Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention

Open access
Trojanowski, John Q., Hampel, Harald · 2011 · Progress in Neurobiology
Cited by 54

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

This special issue of Progress in Neurobiology entitled “Biomarkers for Neurodegenerative Disorders” is a biomarker tour de force as a result of the heroic efforts of the experts in research on chemical and neuroimaging biomarkers of neurodegenerative disorders and related diseases who have contributed superb overviews for this very timely volume. The conditions covered in this special issue range from aging related neurodegenerative diseases that now are epidemic such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), the most common neurodegenerative dementia and movement disorder, respectively, to less common conditions like frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and vascular dementia (VaD). Notably, the incidence and prevalence of these disorders are on the rise due to worldwide demographic trends that are leading to rapidly aging populations across the globe (Khachaturian et al., 2009; The Alzheimer’s Study Group Report, 2008; Trojanowski et al., 2010a,b; Plassman et al., 2007; Hurd et al., 2007; Wimo and Prince, 2010). Moreover, it is becoming increasingly clear that the hallmark lesions of PD, such as alpha-synuclein inclusions known as Lewy bodies, and those shared by ALS and FTLD such as TDP-43 pathology, co-occur in AD thereby rendering insights into biomarkers of PD, ALS and FTLD equally relevant to developing informative biomarkers for the onset and progression of AD (see Table 1). Further, the clinical and pathological overlap of AD with PD, ALS and FTLD make it attractive to be able to monitor biomarker evidence for the presence of AD pathology in the brains of patients with these other disorders. In addition, this special issue also includes chapters on biomarkers for schizophrenia, affective disorders and multiple sclerosis because the editors of this special issue and the authors of the chapters here envision many opportunities for advances in biomarker research in each of these areas of neuropsychiatric disease research to cross fertilize and stimulate progress in other areas of biomarker research including research on neurodegenerative disease biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2011.07.004

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 54

Metadata

Authors
Trojanowski, J. Q., & Hampel, H.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2011-12
Volume
95
Issue
4
Pages
491-495
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2133868311
Cited by
54
References
11
FWCI
1.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. https://app.cochat.ai/papers/10.1016/j.pneurobio.2011.07.004
The paper
Trojanowski, J. Q., & Hampel, H. (2011). Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2011.07.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.